Predicting Potential Market Opportunities of Unavailable "New Drug" Entities in the United States-Regression Model Building

REFERENCES

• Nagasawa, Masako 1985. Identifying potential market opportunities of unavailable "new drug" entities in the United States. Masters thesis, Department of Pharmacy Health Care Administration, College of Pharmacy, University of Florida.
   Google Scholar
• Hass, Arthur E. 1983, November. Where drug marketing patterns are similar. Medical Marketing and Media, pp. 78, 80, 82–83.
   Google Scholar
• Andersen, R., Smedby, B., and Anderson. O. W. 1970. Medical care use in Sweden and the United Stales-A comparative analysis of systems and behavior (Research Series No. 27). Chicago, IL: University of Chicago. Center for Health Administration Studies.
   Google Scholar
• Kohn, R. and White, K. L. 1976. Health care-An international study (Report of the World Health Organization/International Collaborative Study of Medical Care Utilization). London. England: Oxford University Press.
   Google Scholar
• Wilder. C. S. 1966. Cost and acquisition of prescribed and nonprescribed med-icines-United States, July 1964-June 1965 (Public Health Service Publication No. 1000, Series 10. No. 33). National Center for Health Statistics. Washington, DC: U.S. Govern-ment Printing Office.
   Google Scholar
• Dunnell, K. and Cartwright, A. 1972. Medicine-taker, prescribers and hoarders. London and Boston: Routledge & Kegan Paul.
   Google Scholar
• White, K. L. and Murnaghan, J. H. 1969. International comparisons of medical care utilization: A feasibility study (U.S. Department of Health, Education, and Welfare, No. 100. Series 2, No. 33). National Center for Health Statistics. Washington, DC: U.S. Government Printing Office.
   Google Scholar
• Christensen, Dale B. and Bush. Patricia J. 1981. Drug prescribing: Patterns, prob-lems and proposals. Social Science and Medicine. ISA, 343–355.
   Google Scholar
• Rosner, Martin M. and Sarros. Alexander 1972. Determinants of international drug consumption. Journal of the American Pharmaceutical Association, 12, 624–626.
   Google Scholar
• Worthen. Dennis B. 1973. Prescribing influences: An overview. British Journal of Medical Education, 7, 109–117.
   Google Scholar
• Miller, Russell R. 1973. Prescribing habits of physicians, a review of studies on prescribing of drugs, PARTS IV-VI. Drug Intelligence and Clinical Pharmacy, 7. 557–564,
   Google Scholar
• Hemminki, Elina 1975. Review of literature on the factors affecting drug prescrib-ing. Social Science and Medicine, 9, 111–115.
   Google Scholar
• Smith, Mickey C. 1983. Principles of pharmaceutical marketing (3rd Ed.). Philadelphia: Lea & Febiger.
   Google Scholar
• National Center for Health Statistics. 1982. Public use data tape documentation, 1980 national ambulatory medical care survey for drug mentions (P383-154781). Hyatts-ville, MD.
   Google Scholar
• Koch, Hugo and Campbell. William H. 1982. The collection and processing of drug information: National ambulatory medical care survey, United States, 1980. Vital and health statistics. Series 2-No. 90 (DHHS Publication No. (PHS) 82–1364). National Center for Health Statistics. Washington, DC: U.S. Government Printing Office.
   Google Scholar
• Juergens, John P. 1985. The influence of physician and patient characteristics on the prescribing of new prescription drugs. PhD dissertation, Department of Health Care Ad-ministration, School of Pharmacy, University of Mississippi.
   Google Scholar
• National Center for Health Statistics. 1980. International classification of diseases, 9th revision, clinical modification (ICD-9-M) (DHHS Publication No. (PHS) 80–1260). Washington, DC: U.S. Government Printing Office.
   Google Scholar
• American Society of Hospital Pharmacists 1984. Drug information 84. Bethesda, MD.
   Google Scholar
• Coleman, James, Menzel. Herbert, and Katz. Elihu. 1959. Social process in physi-cians' adoption of a new drug. Journal of Chronic Diseases, 9, 1–19.
   Google Scholar
• Strickland, Hodge B. and Jepson, M. H. 1981. Typing prescribers by reaction to medical detailing. Chemist and Druggist, 215, 346, 352.
   Google Scholar
• Petursson, Sigurdun R., Wardell, William M. and Curran, John P. 1978. National rates and patterns of consumption of antihypertensive drugs in relation to their availability in the United States, the United Kingdom, Australia and New Zealand. New York Academy of Science, 304, 320–330.
   Google Scholar
• Smith, Mickey C. 1983. Pn'nciples of pharmaceutical marketing (3rd Ed.). Philadelphia: Lea & Febiger. Chapter 3.
   Google Scholar
• World Health Organization 1979. The selection of essential drugs (Technical Report Series, 641). Geneva, Switzerland.
   Google Scholar
• Knapp, Deanne E. and Oeltjen, Paul D. 1972. Benefits-to-risks ratio in physician drug selection. American Journal of Public Health, 62, 1346–1347.
   Google Scholar
• Harrell, Gilben D. and Bennett, Peter D. 1974. An evaluation of the expectancy value model of attitude measurement for physician prescribing behavior. Journal of Marketing Research, 11, 269–278.
   Web of Science ®Google Scholar
• Lifia, J. 1976. How physicians choose their drugs. Social Science and Medicine, 10, 363–365.
   Google Scholar
• Koch, Hugo 1982. Drug most frequently used in office-based practice: National am-bulatory medical care survey, 1980. Advance data. No. 78 (DHHS Publication No. (PHS) 82–1250). National Center for Health Statistics. Washington, DC: U.S. Government Printing Office.
   Google Scholar
• Koch, Hugo. Telephone conversation with author. March 27, 1986,
   Google Scholar
• Mendenhall, William and McClave, James T. 1981. A second course in business statistics: Regression analysis. California: Dellen Publishing Company, p. 230.
   Google Scholar